Volume 21 Issue 7
Jul.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(7): 1243-1247
GAO Xingfu, GUAN Han, YAN Ruilian, LING Nengyong, LUO Wenhao, WANG Sheng. Expression and clinical significance of CPT2 in renal clear cell carcinoma[J]. Chinese Journal of General Practice, 2023, 21(7): 1243-1247. doi: 10.16766/j.cnki.issn.1674-4152.003093
Citation: GAO Xingfu, GUAN Han, YAN Ruilian, LING Nengyong, LUO Wenhao, WANG Sheng. Expression and clinical significance of CPT2 in renal clear cell carcinoma[J]. Chinese Journal of General Practice, 2023, 21(7): 1243-1247. doi: 10.16766/j.cnki.issn.1674-4152.003093
shu

Expression and clinical significance of CPT2 in renal clear cell carcinoma

doi: 10.16766/j.cnki.issn.1674-4152.003093

  • Department of Urology Surgery, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 2008085QH358

  • Received Date: 2023-02-25
    Available Online: 2023-08-28
    Abstract
  •   Objective  To investigate the differential expression of carnitine palmitoyltransferase 2 (CPT2) in renal clear cell carcinoma (ccRCC) and its correlation with clinical prognosis, in order to provide a new biological therapy target and theoretical basis for the diagnosis and treatment of ccRCC.  Methods  The tumor genome atlas (TCGA) data were first screened to obtain the target gene CPT2. Subsequently, R software was used to analyze the differential expression results of the gene. The clinical data and prognosis downloaded from TCGA was analyzed by R software and visual charts was draw. Immunohistochemistry was used to study the differential expression of this gene in ccRCC tissues and paraneoplastic tissues. Immunohistochemistry was used to study the differential expression of gene in ccRCC tissues and paraneoplastic tissues, and the correlation with clinical data was analyzed.  Results  Using R software to analyze the TCGA database samples, it was found that the expression of CPT2 in paracancerous tissues was higher than that in cancerous tissues (P < 0.05). There was no statistically significant difference in CPT2 expression among patients of different ages and N stages (all P>0.05). There were significant differences in CPT2 expression among patients with different gender, T stage, M stage, clinical stage, pathological grade and overall survival (all P < 0.05). Immunohistochemical results showed that the expression rate of CPT2 in paracancerous tissues (100.0%, 16/16) was higher than that in ccRCC tissues (39.7%, 23/58, P < 0.001). There was a statistically significant difference in CPT2 comparison among patients with different clinical stages (P < 0.05), and there was no statistically significant difference in CPT2 comparison among patients with different gender, T stage, pathological grade, M stage, and age (all P>0.05). The KEGG pathway of CPT2 mainly included adipocyte factor signaling pathway, glucagon signaling pathway, fatty acid degradation, fatty acid metabolism, and PPAR signaling pathway, etc.  Conclusion  CPT2 may be a tumor suppressor gene in renal clear cell carcinoma, which may serve as a potential biological target for early screening and treatment, bringing new programs and directions for the prevention and treatment of renal clear cell carcinoma.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    高五岳, 郭园园, 刘贝贝, 等. 不同距离癌旁组织PD-1和PD-L1表达对肾部分切除术边距选择的临床意义[J]. 中华全科医学, 2019, 17(12): 2004-2007, 2034. doi: 10.16766/j.cnki.issn.1674-4152.001113

    GAO W Y, GUO Y Y, LIU B B, et al. The clinical significances of PD-1 and PD-L1 expressions in different distant tumor adjacent tissues for selecting safe surgical margins in partial nephrectomy[J]. Chinese Journal of General Practice, 2019, 17(12): 2004-2007, 2034. doi: 10.16766/j.cnki.issn.1674-4152.001113
    [2]
    CAO C C, MA Q, HUANG X B, et al. Targeted demethylation of the PLOD2 mRNA inhibits the proliferation and migration of renal cell carcinoma[J]. Front Mol Biosci, 2021, 8: 675683. DOI: 10.3389/fmolb.2021.675683.
    [3]
    ZHANG D, WANG Y C, HU X P. Identification and comprehensive validation of a DNA methylation-driven gene-based prognostic model for clear cell renal cell carcinoma[J]. DNA Cell Biol, 2020, 39(10): 1799-1812. doi: 10.1089/dna.2020.5601
    [4]
    MELONE M A B, VALENTINO A, MARGARUCCI S, et al. The carnitine system and cancer metabolic plasticity[J]. Cell Death Dis, 2018, 9(2): 228. doi: 10.1038/s41419-018-0313-7
    [5]
    YAO M, CAI M, YAO D F, et al. Abbreviated half-lives and impaired fuel utilization in carnitine palmitoyl transferase Ⅱ variant fibroblasts[J]. PLoS One, 2015, 10(3): e0119936. DOI: 10.1371/journal.pone.0119936.
    [6]
    HOUTEN S M, WANDERS R J A, RANEA-ROBLES P. Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(5): 165720. DOI: 10.1016/j.bbadis.2020.165720.
    [7]
    FUJIWARA N, NAKAGAWA N, ENOOKU K, et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity[J]. Gut, 2018, 67(8): 1493-1504. doi: 10.1136/gutjnl-2017-315193
    [8]
    BONNEFONT J P, DJOUADI F, PRIP-BUUS C, et al. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects[J]. Mol Aspects Med, 2004, 25(5-6): 495-520. doi: 10.1016/j.mam.2004.06.004
    [9]
    PEREYRA A S, RAJAN A, FERREIRA C R, et al. Loss of muscle carnitine palmitoyltransferase 2 prevents diet-induced obesity and insulin resistance despite long-chain acylcarnitine accumulation[J]. Cell Rep, 2020, 33(6): 108374. DOI: 10.1016/j.celrep.2020.108374.
    [10]
    GU J J, YAO M, YANG J, et al. Mitochondrial carnitine palmitoyl transferase-Ⅱ inactivity aggravates lipid accumulation in rat hepatocarcinogenesis[J]. World J Gastroenterol, 2017, 23(2): 256-264. doi: 10.3748/wjg.v23.i2.256
    [11]
    PEREYRA A S, HASEK L Y, HARRIS K L, et al. Loss of cardiac carnitine palmitoyltransferase 2 results in rapamycin-resistant, acetylation-independent hypertrophy[J]. J Biol Chem, 2017, 292(45): 18443-18456. doi: 10.1074/jbc.M117.800839
    [12]
    LIN M H, LV D, ZHENG Y L, et al. Downregulation of CPT2 promotes tumorigenesis and chemoresistance to cisplatin in hepatocellular carcinoma[J]. Onco Targets Ther, 2018, 11: 3101-3110. doi: 10.2147/OTT.S163266
    [13]
    HAN S J, WEI R, ZHANG X D, et al. CPT1A/2-mediated FAO enhancement-a metabolic target in radioresistant breast cancer[J]. Front Oncol, 2019, 9: 1201. doi: 10.3389/fonc.2019.01201
    [14]
    LIU J X, LI Y M, XIAO Q, et al. Identification of CPT2 as a prognostic biomarker by integrating the metabolism-associated gene signature in colorectal cancer[J]. BMC Cancer, 2022, 22(1): 1038. doi: 10.1186/s12885-022-10126-0
    [15]
    SUN Z L, JING C Y, XIAO C T, et al. Prognostic risk signature based on the expression of three m6A RNA methylation regulatory genes in kidney renal papillary cell carcinoma[J]. Aging, 2020, 12(21): 22078-22094. doi: 10.18632/aging.104053
    [16]
    PEREYRA A S, HASEK L Y, HARRIS K L, et al. Loss of cardiac carnitine palmitoyltransferase 2 results in rapamycin-resistant, acetylation-independent hypertrophy[J]. J Biol Chem, 2017, 292(45): 18443-18456. doi: 10.1074/jbc.M117.800839
    [17]
    ZHANG X H, ZHANG Z, LIU S J, et al. CPT2 down regulation promotes tumor growth and metastasis through inducing ROS/NFκB pathway in ovarian cancer[J]. Transl Oncol, 2021, 14(4): 101023. DOI: 10.1016/j.tranon.2021.101023.
    [18]
    LI H, CHEN J H, LIU J, et al. CPT2 down regulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism[J]. Exp Cell Res, 2021, 409(1): 112892. DOI: 10.1016/j.yexcr.2021.112892.
    [19]
    GUO X, WANG A M, WANG W, et al. HRD1 inhibits fatty acid oxidation and tumorigenesis by ubiquitinating CPT2 in triple-negative breast cancer[J]. Mol Oncol, 2021, 15(2): 642-656. doi: 10.1002/1878-0261.12856
    [20]
    AIMUDULA A, NASIER H, YANG Y, et al. PPARα mediates sunitinib resistance via NF-κB activation in clear cell renal cell carcinoma[J]. Int J Clin Exp Pathol, 2018, 11(5): 2389-2400.
    [21]
    WU Y F, SONG T, LIU M W, et al. PPARG negatively modulates Six2 in tumor formation of clear cell renal cell carcinoma[J]. DNA Cell Biol, 2019, 38(7): 700-707. doi: 10.1089/dna.2018.4549
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (405) PDF downloads(14) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return